Format
Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 120

1.

High ETS2 expression predicts poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.

Zhang G, Zhang L, Yang X, Zhang X, Zhang J, Yang S, Wang J, Hu K, Shi J, Ke X, Fu L.

Ann Hematol. 2019 Feb;98(2):519-525. doi: 10.1007/s00277-018-3440-4. Epub 2018 Jul 18. No abstract available.

PMID:
30022221
2.

Down-regulation of ETS2 inhibits the invasion and metastasis of renal cell carcinoma cells by inducing EMT via the PI3K/Akt signaling pathway.

Zhang GW, Tian X, Li Y, Wang ZQ, Li XD, Zhu CY.

Biomed Pharmacother. 2018 Aug;104:119-126. doi: 10.1016/j.biopha.2018.05.029. Epub 2018 May 15.

PMID:
29772431
3.

E26 Transformation-Specific Transcription Factor ETS2 as an Oncogene Promotes the Progression of Hypopharyngeal Cancer.

Liu X, Zhang C, Zhang Z, Zhang Z, Ji W, Cao S, Cai X, Lei D, Pan X.

Cancer Biother Radiopharm. 2017 Nov;32(9):327-334. doi: 10.1089/cbr.2017.2296. Epub 2017 Nov 7.

PMID:
29111780
4.

High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions.

Fu L, Fu H, Wu Q, Pang Y, Xu K, Zhou L, Qiao J, Ke X, Xu K, Shi J.

J Transl Med. 2017 Jul 19;15(1):159. doi: 10.1186/s12967-017-1260-2.

5.

Ets2 knockdown inhibits tumorigenesis in esophageal squamous cell carcinoma in vivo and in vitro.

Li Q, Yang L, Han K, Zhu L, Zhang Y, Ma S, Zhang K, Yang B, Guan F.

Oncotarget. 2016 Sep 20;7(38):61458-61468. doi: 10.18632/oncotarget.11369.

6.

A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer.

Hong MJ, Lee SY, Choi JE, Jin CC, Kang HJ, Baek SA, Lee SY, Shin KM, Jeong JY, Lee WK, Yoo SS, Lee J, Cha SI, Kim CH, Son JW, Park JY.

Oncotarget. 2016 Mar 29;7(13):15948-58. doi: 10.18632/oncotarget.7433.

7.

Structural insights into the autoregulation and cooperativity of the human transcription factor Ets-2.

Newman JA, Cooper CD, Aitkenhead H, Gileadi O.

J Biol Chem. 2015 Mar 27;290(13):8539-49. doi: 10.1074/jbc.M114.619270. Epub 2015 Feb 10.

8.

Role for Ets-2(Thr-72) transcription factor in stage-specific thymocyte development and survival.

Fisher IB, Ostrowski M, Muthusamy N.

J Biol Chem. 2012 Feb 17;287(8):5199-210. doi: 10.1074/jbc.M111.242602. Epub 2011 Nov 29.

9.

Differential allelic distribution of V-ets erythroblastosis virus E26 oncogene homolog2 (ETS2) functional polymorphisms in different group of patients.

Chatterjee A, Dutta S, Mukherjee S, Mukherjee N, Chandra S, Mukherjee A, Sinha S, Panda CK, Chaudhuri K, Mukhopadyay K.

Gene Expr. 2010;15(2):61-73.

10.

Effect of different biomaterials on the expression pattern of the transcription factor Ets2 in bone-like constructs.

Sutter W, Stein E, Koehn J, Schmidl C, Lezaic V, Ewers R, Turhani D.

J Craniomaxillofac Surg. 2009 Jul;37(5):263-71. doi: 10.1016/j.jcms.2009.01.007. Epub 2009 Mar 21.

PMID:
19318269
11.

Acute experimental colitis and human chronic inflammatory diseases share expression of inflammation-related genes with conserved Ets2 binding sites.

van der Pouw Kraan TC, Zwiers A, Mulder CJ, Kraal G, Bouma G.

Inflamm Bowel Dis. 2009 Feb;15(2):224-35. doi: 10.1002/ibd.20747.

PMID:
18942749
12.

The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy.

Ge Y, LaFiura KM, Dombkowski AA, Chen Q, Payton SG, Buck SA, Salagrama S, Diakiw AE, Matherly LH, Taub JW.

Leukemia. 2008 Mar;22(3):521-9. Epub 2007 Dec 20.

13.

Expression patterns of Ets2 protein correlate with bone-specific proteins in cell-seeded three-dimensional bone constructs.

Wanschitz F, Stein E, Sutter W, Kneidinger D, Smolik K, Watzinger F, Turhani D.

Cells Tissues Organs. 2007;186(4):213-20. Epub 2007 Aug 16.

PMID:
17703088
14.

Expression pattern of the chromosome 21 transcription factor Ets2 in cell-seeded three-dimensional bone constructs.

Turhani D, Watzinger E, Weissenböck M, Yerit K, Cvikl B, Ewers R, Thurnher D.

J Biomed Mater Res A. 2005 Jun 15;73(4):445-55.

PMID:
15900611
15.

Overexpression of ETS2 in human esophageal squamous cell carcinoma.

Li X, Lu JY, Zhao LQ, Wang XQ, Liu GL, Liu Z, Zhou CN, Wu M, Liu ZH.

World J Gastroenterol. 2003 Feb;9(2):205-8.

16.

Linkage of elevated ets-2 expression to hepatocarcinogenesis.

Ito Y, Miyoshi E, Takeda T, Nagano H, Sakon M, Noda K, Tsujimoto M, Monden M, Matsuura N.

Anticancer Res. 2002 Jul-Aug;22(4):2385-9.

PMID:
12174931
17.

PTEN blocks insulin-mediated ETS-2 phosphorylation through MAP kinase, independently of the phosphoinositide 3-kinase pathway.

Weng LP, Brown JL, Baker KM, Ostrowski MC, Eng C.

Hum Mol Genet. 2002 Jul 15;11(15):1687-96. Erratum in: Hum Mol Genet. 2003 Aug 1;12(15):1943.

PMID:
12095911
18.

Hu-ets-2 is translocated to chromosome 8 in the t(8;21) in acute myelogenous leukemia.

Le Beau MM, Rowley JD, Sacchi N, Watson DK, Papas TS, Diaz MO.

Cancer Genet Cytogenet. 1986 Nov;23(3):269-74.

PMID:
3021321
19.

Molecular organization and differential polyadenylation sites of the human ETS2 gene.

Watson DK, Mavrothalassitis GJ, Jorcyk CL, Smyth FE, Papas TS.

Oncogene. 1990 Oct;5(10):1521-7.

PMID:
2250910
20.

Rapid and transient expression of Ets2 in mature macrophages following stimulation with cMGF, LPS, and PKC activators.

Boulukos KE, Pognonec P, Sariban E, Bailly M, Lagrou C, Ghysdael J.

Genes Dev. 1990 Mar;4(3):401-9.

Supplemental Content

Support Center